 |
|
|
| |
Antiviral Activity and Characterization of Resistance in a Three Day Dose Ranging Study of GS-5885, a Novel HCV NS5A inhibitor
|
| |
| |
Reported by Jules Levin
22nd Conference of the Asian Pacific
Association for the Study of the Liver (APASL)
February 16-19, 2012
Taipei, Taiwan
KA Wong1, A Worth1, R Martin1, E Svarovskaia1, DM Brainard2, JG McHutchison2, E Lawitz3, MD Miller1, H Mo1
1Department of Clinical Virology, Gilead Sciences, Inc., Foster City, CA, USA; 2Department of Clinical Research, Gilead Sciences, Inc., Foster City, CA, USA
3Alamo Medical Research, San Antonio, TX, USA
|
| |
|
|
|
|
|
